Q4 2014 13F Holders as of 31 Dec 2014
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
104,661,494
-
Total 13F shares
-
19,756,513
-
Share change
-
+961,651
-
Total reported value
-
$334,667,612
-
Price per share
-
$16.94
-
Number of holders
-
67
-
Value change
-
+$8,319,858
-
Number of buys
-
38
-
Number of sells
-
37
Institutional Holders of Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) as of Q4 2014
As of 31 Dec 2014,
Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) was held by
67 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
19,756,513 shares.
The largest 10 holders included
Essex Woodlands Health Ventures, Inc., NQ HCIF GP, Ltd., FRANKLIN RESOURCES INC, Polar Capital LLP, Bank of New York Mellon Corp, Visium Asset Management, LP, Arrowpoint Asset Management, LLC, JPMORGAN CHASE & CO, ALLIANCEBERNSTEIN L.P., and BlackRock Fund Advisors.
This page lists
67
institutional shareholders reporting positions in this security
for the Q4 2014 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.